Compile Data Set for Download or QSAR
Report error Found 14131 of affinity data for UniProtKB/TrEMBL: Q9NWZ3
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50515378(CHEMBL4443947)
Affinity DataIC50: 0.0220nMAssay Description:Binding affinity to human IRK4 using myelin basic protein as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50511360(CHEMBL4556091)
Affinity DataIC50: 0.0260nMAssay Description:Inhibition of IRAK4 in human whole blood assessed as inhibition of R848-induced IL-6 production preincubated for 90 mins followed by R848 stimulation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50599226(CHEMBL5201062 | US11866405, Example 100)
Affinity DataIC50: 0.0300nMAssay Description:Inhibition of recombinant human full-length His-tagged IRAK4 expressed in baculovirus infected insect cells using KKARFSRFAGSSPSQSSMVAR as substrate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50599226(CHEMBL5201062 | US11866405, Example 100)
Affinity DataIC50: 0.0300nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50511348(CHEMBL4566431 | US11034698, Example 105)
Affinity DataIC50: 0.0780nMAssay Description:Inhibition of IRAK4 in human whole blood assessed as inhibition of R848-induced IL-6 production preincubated for 90 mins followed by R848 stimulation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50511359(CHEMBL4545898 | US10988478, Example 258)
Affinity DataIC50: 0.0810nMAssay Description:Inhibition of IRAK4 in human whole blood assessed as inhibition of R848-induced IL-6 production preincubated for 90 mins followed by R848 stimulation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50515375(CHEMBL4448950)
Affinity DataIC50: 0.0990nMAssay Description:Binding affinity to human IRK4 using myelin basic protein as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM403214(US10329302, Example 370 | US10793579, Example 370 ...)
Affinity DataIC50: 0.100nMAssay Description:Protocol B: To begin the assay, 45 μL of reaction mixture containing 20 mM HEPES pH=7.5, 5 mM MgCl2, 0.0025% Brij-35, 600 μM ATP, 228 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50239499(CHEMBL4081711 | US10329302, Example 344 | US107935...)
Affinity DataIC50: 0.100nMAssay Description:This is an in vitro assay to measure IRAK4 enzymatic activity utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, Perkin-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665897(US20240116922, Comparator 3A)
Affinity DataIC50: 0.100nMAssay Description:The 2-hour 1 mM ATP Biochemical Assay employed a MesoScale Detection (MSD) format. The kinase reaction was based on the IRAK4 phosphorylation of a bi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM403204(US10329302, Example 360 | US10793579, Example 360 ...)
Affinity DataIC50: 0.100nMAssay Description:Protocol B: To begin the assay, 45 μL of reaction mixture containing 20 mM HEPES pH=7.5, 5 mM MgCl2, 0.0025% Brij-35, 600 μM ATP, 228 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM403214(US10329302, Example 370 | US10793579, Example 370 ...)
Affinity DataIC50: 0.100nMAssay Description:This is an in vitro assay to measure IRAK4 enzymatic activity utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, Perkin-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665704(US20240116922, Example 6)
Affinity DataIC50: 0.100nMAssay Description:The 2-hour 1 mM ATP Biochemical Assay employed a MesoScale Detection (MSD) format. The kinase reaction was based on the IRAK4 phosphorylation of a bi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665703(US20240116922, Example 5)
Affinity DataIC50: 0.100nMAssay Description:The 2-hour 1 mM ATP Biochemical Assay employed a MesoScale Detection (MSD) format. The kinase reaction was based on the IRAK4 phosphorylation of a bi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50239500(CHEMBL4066705 | US10329302, Example 337 | US107935...)
Affinity DataIC50: 0.100nMAssay Description:This is an in vitro assay to measure IRAK4 enzymatic activity utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, Perkin-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665806(US20240116922, Example 108 | (R)-N-(1-cyclopropyl-...)
Affinity DataIC50: 0.100nMAssay Description:The 2-hour 1 mM ATP Biochemical Assay employed a MesoScale Detection (MSD) format. The kinase reaction was based on the IRAK4 phosphorylation of a bi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50239500(CHEMBL4066705 | US10329302, Example 337 | US107935...)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of N-terminal His6-tagged human full length IRAK4 preincubated for 20 mins followed by biotinylated-AGAGRDKYKTLRQIR substrate addition in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/22/2019
Entry Details Article
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50239500(CHEMBL4066705 | US10329302, Example 337 | US107935...)
Affinity DataIC50: 0.100nMAssay Description:This is an in vitro assay to measure IRAK4 enzymatic activity utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, Perkin-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM319575(5-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-...)
Affinity DataIC50: 0.100nMAssay Description:This is an in vitro assay to measure IRAK4 enzymatic activity utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, Perkin-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2019
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665883(US20240116922, Example 185)
Affinity DataIC50: 0.100nMAssay Description:The 2-hour 1 mM ATP Biochemical Assay employed a MesoScale Detection (MSD) format. The kinase reaction was based on the IRAK4 phosphorylation of a bi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50652763(CHEMBL5646411 | US20250268877, Example 84)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of IRAK4 (unknown origin) incubated for 1 hr in presence of ATP by Mesoscale assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50239499(CHEMBL4081711 | US10329302, Example 344 | US107935...)
Affinity DataIC50: 0.100nMAssay Description:Protocol B: To begin the assay, 45 μL of reaction mixture containing 20 mM HEPES pH=7.5, 5 mM MgCl2, 0.0025% Brij-35, 600 μM ATP, 228 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50239500(CHEMBL4066705 | US10329302, Example 337 | US107935...)
Affinity DataIC50: 0.100nMAssay Description:Protocol B: To begin the assay, 45 μL of reaction mixture containing 20 mM HEPES pH=7.5, 5 mM MgCl2, 0.0025% Brij-35, 600 μM ATP, 228 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665859(US20240116922, Example 161 | 7-((S)-sec-butoxy)-N-...)
Affinity DataIC50: 0.100nMAssay Description:The 2-hour 1 mM ATP Biochemical Assay employed a MesoScale Detection (MSD) format. The kinase reaction was based on the IRAK4 phosphorylation of a bi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50239500(CHEMBL4066705 | US10329302, Example 337 | US107935...)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of full-length IRAK4 (unknown origin) in presence of ATP by DELFIA assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/16/2024
Entry Details
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665863(US20240116922, Example 165 | N-(1-((1R,2S)-2-fluor...)
Affinity DataIC50: 0.100nMAssay Description:The 2-hour 1 mM ATP Biochemical Assay employed a MesoScale Detection (MSD) format. The kinase reaction was based on the IRAK4 phosphorylation of a bi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50599222(CHEMBL5190644 | US11866405, Example 12)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant human full-length His-tagged IRAK4 expressed in baculovirus infected insect cells using KKARFSRFAGSSPSQSSMVAR as substrate ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM403204(US10329302, Example 360 | US10793579, Example 360 ...)
Affinity DataIC50: 0.100nMAssay Description:This is an in vitro assay to measure IRAK4 enzymatic activity utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, Perkin-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665902(US20240116922, Comparator 5A)
Affinity DataIC50: 0.100nMAssay Description:The 2-hour 1 mM ATP Biochemical Assay employed a MesoScale Detection (MSD) format. The kinase reaction was based on the IRAK4 phosphorylation of a bi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50599222(CHEMBL5190644 | US11866405, Example 12)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of compounds against IRAK4 were determined in an enzymatic assay using mass spectrometry readout. Ten point half-log compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2024
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM403214(US10329302, Example 370 | US10793579, Example 370 ...)
Affinity DataIC50: 0.100nMAssay Description:This is an in vitro assay to measure IRAK4 enzymatic activity utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, Perkin-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM403204(US10329302, Example 360 | US10793579, Example 360 ...)
Affinity DataIC50: 0.100nMAssay Description:This is an in vitro assay to measure IRAK4 enzymatic activity utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, Perkin-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/31/2020
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50239499(CHEMBL4081711 | US10329302, Example 344 | US107935...)
Affinity DataIC50: 0.100nMAssay Description:This is an in vitro assay to measure IRAK4 enzymatic activity utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, Perkin-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665912(US20240116922, Comparator 3B)
Affinity DataIC50: 0.100nMAssay Description:The 2-hour 1 mM ATP Biochemical Assay employed a MesoScale Detection (MSD) format. The kinase reaction was based on the IRAK4 phosphorylation of a bi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50511361(CHEMBL4445098)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of IRAK4 in human whole blood assessed as inhibition of R848-induced IL-6 production preincubated for 90 mins followed by R848 stimulation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50511366(CHEMBL4568894)
Affinity DataIC50: 0.110nMAssay Description:Inhibition of IRAK4 in human whole blood assessed as inhibition of R848-induced IL-6 production preincubated for 90 mins followed by R848 stimulation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50511358(CHEMBL4472406 | US10988478, Example 175)
Affinity DataIC50: 0.160nMAssay Description:Inhibition of IRAK4 in human whole blood assessed as inhibition of R848-induced IL-6 production preincubated for 90 mins followed by R848 stimulation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665809(US20240116922, Example 111 | N-(1-cyclopropyl-2-ox...)
Affinity DataIC50: 0.160nMAssay Description:Inhibition of human IRAK4 using biotinylated peptide substrate incubated for 3 hrs by microplate reader assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665891(US20240116922, Comparator 1A)
Affinity DataIC50: 0.170nMAssay Description:Inhibition of IRAK4 (unknown origin) using biotinylated peptide (IRAK1 activation loop sequence 360-389) as substrate incubated for 2 hrs in presence...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50636469(CHEMBL5549771)
Affinity DataIC50: 0.170nMAssay Description:Inhibition of human IRAK4 using biotinylated peptide substrate incubated for 3 hrs by microplate reader assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665787(US20240116922, Example 89 | 2-(2-oxabicyclo[2.1.1]...)
Affinity DataIC50: 0.190nMAssay Description:Inhibition of human IRAK4 using biotinylated peptide substrate incubated for 3 hrs by microplate reader assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50511349(CHEMBL4475494 | US10988478, Example 139)
Affinity DataIC50: 0.190nMAssay Description:Inhibition of IRAK4 in human whole blood assessed as inhibition of R848-induced IL-6 production preincubated for 90 mins followed by R848 stimulation...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50636471(CHEMBL5532502)
Affinity DataIC50: 0.190nMAssay Description:Inhibition of human IRAK4 using biotinylated peptide substrate incubated for 3 hrs by microplate reader assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665861(US20240116922, Example 163 | N-(1-((1R,2S)-2-fluor...)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of human IRAK4 using biotinylated peptide substrate incubated for 3 hrs by microplate reader assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM402999(US10329302, Example 146 | US10793579, Example 146 ...)
Affinity DataIC50: 0.200nMAssay Description:This is an in vitro assay to measure IRAK4 enzymatic activity utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, Perkin-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665828(US20240116922, Example 130)
Affinity DataIC50: 0.200nMAssay Description:The 2-hour 1 mM ATP Biochemical Assay employed a MesoScale Detection (MSD) format. The kinase reaction was based on the IRAK4 phosphorylation of a bi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM665699(US20240116922, Example 1)
Affinity DataIC50: 0.200nMAssay Description:The 2-hour 1 mM ATP Biochemical Assay employed a MesoScale Detection (MSD) format. The kinase reaction was based on the IRAK4 phosphorylation of a bi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50095475(CHEMBL3590479)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of IRAK4 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/18/2016
Entry Details Article
PubMed
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50239499(CHEMBL4081711 | US10329302, Example 344 | US107935...)
Affinity DataIC50: 0.200nMAssay Description:Protocol B: To begin the assay, 45 μL of reaction mixture containing 20 mM HEPES pH=7.5, 5 mM MgCl2, 0.0025% Brij-35, 600 μM ATP, 228 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/14/2021
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetInterleukin-1 receptor-associated kinase 4(Human)
Glaxosmithkline Medicines Research Centre

Curated by ChEMBL
LigandPNGBDBM50239499(CHEMBL4081711 | US10329302, Example 344 | US107935...)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of N-terminal His6-tagged human full length IRAK4 preincubated for 20 mins followed by biotinylated-AGAGRDKYKTLRQIR substrate addition in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/22/2019
Entry Details Article
PubMedPDB3D3D Structure (crystal)
Displayed 1 to 50 (of 14131 total ) | Next | Last >>
Jump to: